8-K: Schrödinger Reports Strong First Quarter 2025 Financial Results, Driven by Software and Drug Discovery Revenue Growth

Schrödinger's first quarter 2025 results show a 63% increase in total revenue, driven by strong performance in both software and drug discovery segments, with initial clinical data for SGR-1505 expected in June.

Summary

• Schrödinger announced its financial results for the first quarter ended March 31, 2025.
• Total revenue for the first quarter increased by 63% to $59.6 million, compared to $36.6 million in the first quarter of 2024.
• Software revenue increased by 46% to $48.8 million, driven by early renewals and increases in hosted contracts.
• Drug discovery revenue was $10.7 million, a significant increase from $3.2 million in the first quarter of 2024, including $5.7 million from the Novartis collaboration.
• Software gross margin was 72%, compared to 76% in the first quarter of 2024, due to costs associated with the predictive toxicology initiative.
• Operating expenses decreased to $82.0 million from $86.3 million, primarily due to lower R&D expenses.
• Net loss for the quarter was $59.8 million, compared to $54.7 million in the first quarter of 2024.
• The company maintains its 2025 financial guidance, expecting software revenue growth of 10% to 15% and drug discovery revenue between $45 million and $50 million.
• For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and progress in clinical programs. While the net loss increased, the company maintains its financial guidance and expects continued growth, indicating a generally optimistic sentiment.

Positives

• Significant revenue growth in both software and drug discovery segments.
• Strong performance driven by early software renewals and increased hosted contracts.
• Advancement of proprietary pipeline with multiple clinical-stage programs.
• Collaboration with Novartis contributing significantly to drug discovery revenue.
• Operating expenses decreased, primarily due to lower R&D expenses.
• Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.

Negatives

• Net loss increased to $59.8 million from $54.7 million year-over-year.
• Software gross margin decreased to 72% from 76%, attributed to the predictive toxicology initiative.
• Other expense was $8.9 million for the first quarter, which included changes in fair value of equity investments and interest income/expense, compared to other income of $13.2 million for the first quarter of 2024.

Risks

• The company's reliance on third-party providers of cloud-based infrastructure to host its software solutions.
• Uncertainties inherent in drug development and commercialization, including the timing and ability to initiate and complete preclinical studies and clinical trials.
• The ability to retain and hire key personnel.
• Fluctuations in the value of the U.S. dollar and foreign currencies.
• The demand for its software platform.

Future Outlook

Schrödinger maintains its 2025 financial guidance, expecting software revenue growth of 10% to 15% and drug discovery revenue between $45 million and $50 million. Software gross margin is expected to range from 74% to 75%. Operating expense growth in 2025 is expected to be less than 5%. Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024. For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.

Management Comments

• 'We are very pleased with Schrdinger's performance in the first quarter of 2025, with strong software and drug discovery revenue growth,' said Ramy Farid, Ph.D., chief executive officer of Schrdinger.
• Dr. Farid also noted that the pharmaceutical industry and regulatory agencies are seeking to increase usage of computational solutions in R&D.
• Management believes the company has a solid foundation for long-term growth due to its growing software business and advancing pipeline.

Industry Context

The announcement highlights the increasing adoption of computational solutions in pharmaceutical R&D, aligning with industry trends and regulatory initiatives to reduce animal testing. Schrödinger is positioning itself as a key player in this space with its software platform and drug discovery programs.

Comparison to Industry Standards

• Schrödinger's software revenue growth of 46% significantly outpaces the average growth rate for the computational chemistry software market, which is estimated to be around 10-15%.
• Companies like Dassault Systèmes BIOVIA and ChemAxon are key competitors in the software space, but Schrödinger's focus on integrating software with proprietary drug discovery programs differentiates it.
• The $5.7 million revenue from the Novartis collaboration demonstrates the value of Schrödinger's platform in supporting large pharmaceutical companies' drug discovery efforts, comparable to similar collaborations between other biotech firms and major pharma.
• Schrödinger's clinical-stage oncology programs, such as the MALT1 inhibitor SGR-1505, are in direct competition with other companies developing targeted therapies for B-cell malignancies, including those from companies like AbbVie and Roche.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth and maintained financial guidance.
• Employees: Positive impact due to company growth and advancement of drug discovery programs.
• Customers: Positive impact due to advancements in the software platform and predictive toxicology initiative.
• Collaborators: Positive impact due to continued progress in collaborative drug discovery programs.

Next Steps

• Reporting initial clinical data from the Phase 1 study of SGR-1505 in June.
• Continuing to progress the Phase 1 clinical studies of SGR-2921 and SGR-3515, with initial data expected in the second half of 2025.
• Advancing the predictive toxicology initiative, expected to be available to customers in the second half of 2025.

Key Dates

Keywords

Schrödinger, financial results, software revenue, drug discovery, SGR-1505, clinical trials, computational platform, revenue growth, pharmaceutical, biotechnology